Predictive biomarkers and initial analysis of maternal immune alterations in postpartum preeclampsia reveal an immune-driven pathology

• DOI: 10.3389/fimmu.2024.1380629
• Publication Date: 2024-04-30T04:20:44Z
• Authors: Camille Couture; Marie-Eve Brien; Jade Rechtzigel; SuYun Ling; Cecilia Ledezma-Soto; Gilberto Duran Bi...; Ines Boufaied; Dorothée Dal Soglio; Evelyne Rey; Serge McGraw; Charles H. Graham; Sylvie Girard
• Keywords: Cord blood

Introduction Postpartum preeclampsia (PPPE) is an under-diagnosed condition, developing within 48 hours to 6 weeks following uncomplicated pregnancy. The etiology of PPPE still unknown, leaving patients vulnerable and making the identification treatment requiring postpartum care unmet need. We aimed understand immune contribution at time diagnosis, as well uncover predictive potential perinatal biomarkers for early postnatal high-risk patients. Methods Placentas were collected delivery from pregnancies (CTL) immunohistochemistry analysis. In this initial study, blood samples in diagnosis (48h-25 days postpartum; mean 7.4 days) compared CTL taken 24h after delivery. Single-cell transcriptomics, flow cytometry, intracellular cytokine staining, circulating levels inflammatory mediators evaluated blood. Results Placental CD163+ cells 1 st trimester pressures can be valuable non-invasive with strong clinical application prospects. Furthermore, changes cell populations, production by CD14+, CD4+, CD8+ cells, suggested a dampened response exhausted phenotype including decreased IL1β, IL12, IFNγ elevated IL10. Discussion Understanding maternal prenatally placenta our sizable cohort will serve groundwork pre-clinical research, guiding practice example development immune-targeted therapies, who would benefit more thorough follow-ups risk education